Skip to main content
Equibles
ANIK logo

ANIK · Anika Therapeutics, Inc.

Track ANIK — free

Use ANIK with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about ANIK

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$21.50 +0.33 (+1.56%) At close · Aug 14
Customer concentration — top customer 53% of revenue

One customer — 53% of revenue (the three months ended June 30, 2026)

“Revenue from the Company’s sole significant customer, Johnson & Johnson MedTech (“J&J MedTech”), part of the Johnson & Johnson Medical Companies, as a percentage of the Company’s total revenue was 53% and 50% for the three-months ended June 30, 2026, and 2025, respectively, and 50% for the six-months ended June 30, 2026, and 2025.”

One customer — 50% of revenue (the six months ended June 30, 2026)

“Revenue from the Company’s sole significant customer, Johnson & Johnson MedTech (“J&J MedTech”), part of the Johnson & Johnson Medical Companies, as a percentage of the Company’s total revenue was 53% and 50% for the three-months ended June 30, 2026, and 2025, respectively, and 50% for the six-months ended June 30, 2026, and 2025.”
View the 10-Q filed Jul 29, 2026
Market Cap
$287.73M
Shares
13.38M

Anika Therapeutics, Inc. Earnings Call Transcripts

Every quarterly earnings call for Anika Therapeutics, Inc. (ANIK) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲1.8% $40.26M −$4.17M '22 Q3 22-11-08 ▼107.8% $ −$4.91M '22 Q4 23-03-06 ▲3.4% $37.92M −$10.35M '23 Q1 23-05-09 ▲11.7% $44.30M −$2.74M '23 Q2 23-08-08 ▲3% $41.47M −$6.58M '23 Q3 23-11-02 · $ −$63.00M '23 Q4 24-03-13 ▼23.5% $29.02M −$4.51M '24 Q1 24-05-08 ▼30.6% $30.72M −$88,000 '24 Q2 24-08-08 ▼28.7% $29.56M −$29.92M '24 Q3 24-10-31 · $30.60M −$21.86M '24 Q4 25-03-12 ▼9.8% $26.17M −$4.87M '25 Q1 25-05-09 ▼8.2% $28.22M −$3.97M '25 Q2 25-07-30 ▼5.9% $27.82M −$2.33M '25 Q3 25-11-05 ▲0% $30.61M $292,000 '25 Q4 26-02-26 ▲13.2% $29.61M −$5.06M '26 Q1 26-04-29 LATEST ▲15.6% $32.61M $3.31M '26 Q2 26-07-29
Earnings call
FY26 · Q2
2026-07-29
Q2 2026 Anika Therapeutics Earnings Conference Call
Confident tone International OA pain management growth OEM channel and J&J / DePuy Synthes partnership Operational excellence and margin expansion
Revenue
$32.61M
▲ 15.6% YoY
Diluted EPS
$0.24
Gross margin
65.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-04-29
Anika Therapeutics, Inc. Q1 FY2026 Earnings Call
Confident tone Integrity regenerative product performance Operational discipline and gross margin International OA Pain Management
Revenue
$29.61M
▲ 13.2% YoY
Diluted EPS
$-0.37
Gross margin
64.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
Anika Therapeutics, Inc. Q4 FY2025 Earnings Call
Positive tone Commercial channel revenue growth International OA pain portfolio Integrity regenerative platform
Revenue
$30.61M*
▲ 0% YoY
Gross margin
62.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-05
Anika Therapeutics, Inc. Q3 FY2025 Earnings Call
Positive tone Hyalofast Regulatory Pathway Cingal NDA Progress Integrity Adoption
Revenue
$27.82M
▼ 5.9% YoY
Diluted EPS
$-0.16
Gross margin
56.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-07-30
Anika Therapeutics, Inc. Q2 FY2025 Earnings Call
Cautious tone Hyalofast Phase III Trial Results Cingal NDA Progress Integrity Product Momentum
Revenue
$28.22M
▼ 8.2% YoY
Diluted EPS
$-0.28
Gross margin
50.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-09
Anika Therapeutics, Inc. Q1 FY2025 Earnings Call
Balanced tone Commercial channel growth Integrity implant traction Supply and production issues
Revenue
$26.17M
▼ 9.8% YoY
Diluted EPS
$-0.34
Gross margin
56.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-12
Anika Therapeutics, Inc. Q4 FY2024 Earnings Call
Positive tone Integrity Implant System Growth Hyalofast Regulatory Progress Cingal Development
Revenue
$30.60M*
Gross margin
56.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-10-31
Anika Therapeutics, Inc. Q3 FY2024 Earnings Call
Positive tone Regenerative Solutions pipeline OA Pain Management focus Strategic restructuring and divestitures
Revenue
$29.56M
▼ 28.7% YoY
Diluted EPS
$-2.03
Gross margin
65.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Anika Therapeutics, Inc. Q2 FY2024 Earnings Call
Confident tone Regenerative product Integrity launch OA Pain Management franchise (Orthovisc/Monovisc/Cingal) Regulatory pipeline and clinical studies
Revenue
$30.72M
▼ 30.6% YoY
Diluted EPS
$0.00
Gross margin
66.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
Anika Therapeutics, Inc. Q1 FY2024 Earnings Call
Positive tone OA Pain Management Cingal U.S. FDA Path Joint Preservation and Restoration
Revenue
$29.02M
▼ 23.5% YoY
Diluted EPS
$-0.31
Gross margin
65.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-13
Anika Therapeutics, Inc. Q4 FY2023 Earnings Call
Confident tone 2024 guidance and MDR / international Integrity Implant System OA Pain Management / Cingal
Revenue
$*
Gross margin
-199.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Anika Therapeutics, Inc. Q3 FY2023 Earnings Call
Revenue
$41.47M
▲ 3% YoY
Diluted EPS
$-0.45
Gross margin
60.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Anika Therapeutics, Inc. Q2 FY2023 Earnings Call
Revenue
$44.30M
▲ 11.7% YoY
Diluted EPS
$-0.19
Gross margin
65.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
Anika Therapeutics, Inc. Q1 FY2023 Earnings Call
Revenue
$37.92M
▲ 3.4% YoY
Diluted EPS
$-0.71
Gross margin
60.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-06
Anika Therapeutics, Inc. Q4 FY2022 Earnings Call
Revenue
$*
▼ 107.8% YoY
Gross margin
-135.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-08
Anika Therapeutics, Inc. Q3 FY2022 Earnings Call
Revenue
$40.26M
▲ 1.8% YoY
Diluted EPS
$-0.29
▼ 825% YoY
Gross margin
56.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-03
Anika Therapeutics, Inc. Q2 FY2022 Earnings Call
Revenue
$39.66M
▲ 4% YoY
Diluted EPS
$-0.20
▼ 144.4% YoY
Gross margin
62.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Anika Therapeutics, Inc. Q1 FY2022 Earnings Call
Revenue
$36.69M
▲ 7% YoY
Diluted EPS
$-0.20
▼ 200% YoY
Gross margin
59.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-08
Anika Therapeutics, Inc. Q4 FY2021 Earnings Call
Revenue
$35.82M*
▲ 9.6% YoY
Gross margin
50.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-04
Anika Therapeutics, Inc. Q3 FY2021 Earnings Call
Revenue
$39.54M
▲ 24.7% YoY
Diluted EPS
$0.04
Gross margin
58.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
Anika Therapeutics, Inc. Q2 FY2021 Earnings Call
Revenue
$38.15M
▲ 24.3% YoY
Diluted EPS
$0.45
Gross margin
54.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Anika Therapeutics, Inc. Q1 FY2021 Earnings Call
Revenue
$34.29M
▼ 3.1% YoY
Diluted EPS
$0.20
▼ 50% YoY
Gross margin
61.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-04
Anika Therapeutics, Inc. Q4 FY2020 Earnings Call
Revenue
$32.69M
▲ 9.8% YoY
Diluted EPS
$-1.10
▼ 492.9% YoY
Gross margin
51.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-04
Anika Therapeutics, Inc. Q3 FY2020 Earnings Call
Revenue
$31.69M
▲ 6.7% YoY
Diluted EPS
$-0.45
▼ 168.2% YoY
Gross margin
54.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-07-30
Anika Therapeutics, Inc. Q2 FY2020 Earnings Call
Revenue
$30.68M
▲ 0.9% YoY
Diluted EPS
$-0.54
▼ 180.6% YoY
Gross margin
44.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
Anika Therapeutics, Inc. Q1 FY2020 Earnings Call
Revenue
$35.40M
▲ 43.2% YoY
Diluted EPS
$0.40
▲ 29% YoY
Gross margin
59.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-02-20
Anika Therapeutics, Inc. Q4 FY2019 Earnings Call
Revenue
$29.77M
▲ 10.4% YoY
Diluted EPS
$0.28
▼ 48.1% YoY
Gross margin
70.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–27 of 27 earnings calls
Key facts CIK 898437 CUSIP 035255108 13F (30d) 125 filings 124 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)